Q1 Earnings Estimate for Longeveron Issued By Roth Capital

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Roth Capital lifted their Q1 2025 earnings per share estimates for shares of Longeveron in a research note issued to investors on Monday, March 3rd. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.36). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.40) EPS.

Several other research firms have also commented on LGVN. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Longeveron in a research report on Monday. Roth Mkm assumed coverage on Longeveron in a research report on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective on the stock.

Longeveron Trading Up 2.9 %

Shares of LGVN opened at $1.44 on Thursday. The firm has a market capitalization of $21.37 million, a P/E ratio of -0.23 and a beta of 0.37. The stock’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $1.89. Longeveron has a twelve month low of $0.77 and a twelve month high of $6.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Longeveron in the fourth quarter valued at about $35,000. Northern Trust Corp purchased a new stake in shares of Longeveron during the fourth quarter worth about $31,000. Virtu Financial LLC purchased a new stake in shares of Longeveron during the fourth quarter worth about $53,000. Geode Capital Management LLC increased its position in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after acquiring an additional 97,953 shares during the last quarter. Finally, State Street Corp purchased a new stake in shares of Longeveron during the third quarter worth about $29,000. 10.01% of the stock is owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.